Wegovy Injection, Solution
Product Images NDC 50090-5824

Product Visual Gallery

This gallery contains 19 technical images submitted to the FDA as part of the official labeling for Wegovy (NDC 50090-5824). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Table 1 (Image 01)

A data table displaying weight in pounds and kilograms across the top and height in inches and centimeters along the side. Cells contain numerical values with some highlighted in green, possibly representing specific measurements or thresholds related to weight and height correlations.*

FDA Label Image

Structural Formula (Image 02)

Chemical structure diagram of semaglutide, the active ingredient in WEGOVY .25 mg/0.5 mL subcutaneous injection by A-S Medication Solutions. The structure shows a peptide chain with labeled amino acid residues and attached chemical groups.*

FDA Label Image

Fig 2 (Image 03)

A forest plot showing the relative exposure (Cavg) ratio and 90% confidence intervals for semaglutide injection in WEGOVY across various intrinsic factors including sex, age groups, race, ethnicity, body weight, renal function, and injection site (thigh versus upper arm). The graph compares the pharmacokinetic variability with a reference line at 1.0.*

FDA Label Image

Fig 3 (Image 04)

A forest plot chart depicting relative exposure ratios and 90% confidence intervals for co-administered medications with WEGOVY (semaglutide). Medications include Metformin, S-warfarin, R-warfarin, Digoxin, Atorvastatin, Ethinylestradiol, and Levonorgestrel, shown with respective pharmacokinetic parameters AUC and Cmax plotted against a horizontal axis ranging roughly from 0.5 to 2.*

FDA Label Image

Fig 4 (Image 05)

A cumulative frequency plot comparing percentage change in body weight between WEGOVY and placebo groups. The x-axis shows change in body weight (%) ranging from -40% to 40%, and the y-axis shows cumulative frequency (%) from 0 to 100%. Solid and dashed lines represent WEGOVY and placebo respectively.*

FDA Label Image

Fig 5 (Image 06)

A line graph displaying cumulative frequency (%) on the y-axis versus change in body weight (%) on the x-axis. It compares the weight change distributions for WEGOVY injection, solution (semaglutide) and placebo groups, illustrating differences in percent body weight change over a range of values.*

FDA Label Image

Fig 6 (Image 07)

This image displays two line graphs illustrating the percentage change in body weight over a period of up to 68 weeks, comparing WEGOVY (semaglutide) and placebo groups. The x-axes represent time in weeks, while the y-axes show the percentage change in body weight. Both graphs include data points with corresponding group sizes at various weeks.*

FDA Label Image

Fig 7 (Image 08)

Two line graphs comparing changes in body weight percentage over a period of days for WEGOVY (semaglutide) versus placebo. Both graphs show WEGOVY groups with a greater reduction in body weight compared to placebo over time, with numerical values indicated at data points.*

FDA Label Image

Strength (Image 09)

WEGOVY injection, solution subcutaneous dosage form in various strengths displayed in color-coded boxes: 0.25 mg/0.5 mL in blue, 0.5 mg/0.5 mL in red, 1 mg/0.5 mL in orange, 1.7 mg/0.75 mL in blue, and 2.4 mg/0.75 mL in purple, indicating dosage strength per volume. Labeler A-S Medication Solutions.*

FDA Label Image

Ifu 1 (Image 10)

An instructional illustration showing the WEGOVY injection pen with a label indicating semaglutide 0.25 mg/0.5 mL. It includes a prompt to "Pull out to get started" and a visual guide demonstrating how to prepare the injection by extending the pen.*

FDA Label Image

Ifu 2 (Image 11)

An instructional diagram showing parts and usage of the WEGOVY pen containing semaglutide injection, 0.25 mg/0.5 mL. The image shows the pen before and after use, highlighting the expiration date location, pen window to check medicine clarity, needle cover to conceal the needle, pen cap removal instruction, and a yellow bar indicating dose completion after injection.*

FDA Label Image

Ifu 3 (Image 12)

An instructional diagram showing recommended subcutaneous injection sites for WEGOVY (semaglutide). Areas indicated for injection include the upper arms, stomach, and upper legs, depicted on a simplified human figure.*

FDA Label Image

Click Image (Image 13)

An instructional diagram showing the steps for using the WEGOVY injection pen. It includes three stages: 'Click 1' indicating the injection start, 'Click 2' instructing to hold for a few seconds until the yellow bar stops moving, and a final image showing the yellow bar fully stopped indicating injection completion, with advice to lift the pen slowly. A note states the injection takes about 5-10 seconds.*

FDA Label Image

Sharp Container (Image 14)

An instructional illustration showing a hand holding a semaglutide injection pen connected to a needle, inserting it into a biohazard sharps disposal container. The image demonstrates proper disposal of the injection pen and needle after use.*

FDA Label Image

Caution (Image 15)

FDA Label Image

Contact (Image 16)

WEGOVY 0.25 mg/0.5 mL injection solution in a single-dose, prefilled pen for subcutaneous use. The label includes dosing information and usage instructions, and displays the labeler A-S Medication Solutions. The packaging is primarily white with green and black text.*

FDA Label Image

Step 3 (Image 22)

An instructional illustration showing the removal of the pen cap from a WEGOVY (semaglutide) injection pen. The image highlights the pen cap being pulled downward to reveal the needle inside the subcutaneous injection pen device.*

FDA Label Image

Step 4 (Image 23)

An instructional illustration showing a hand holding a Wegovy 0.25 mg/0.5 mL subcutaneous injection pen, labeled with the product name and dosage strength. The image depicts the injection pen being positioned for administration with a downward arrow indicating direction, likely demonstrating proper use or injection technique.*

FDA Label Image

Label Image (Lbl500905824)

WEGOVY 0.25 mg/0.5 mL injection label for semaglutide solution, subcutaneous route. The label indicates a single-dose prefilled pen with a lot number and storage instructions to store in refrigerator at 36°F to 46°F, protecting from light. Labeler is A-S Medication Solutions, Libertyville, IL, with NDC 50090-5824.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.